(Reuters) – U.S. genetic testing Illumina on Thursday trimmed its annual profit forecast for the second straight quarter, hurt by weakness in demand for its sequencing instruments, consumables and services.…
By Mike Scarcella (Reuters) – A U.S. appeals court on Tuesday said it will accelerate reviewing Illumina Inc’s challenge to a federal agency order requiring the biotechnology company to divest…
By Blake Brittain (Reuters) – Gene-sequencing giant Illumina Inc has settled a patent lawsuit brought by Maryland biotech company Ravgen Inc, which accused Illumina’s genetic tests of infringing its patents.…
(Reuters) – Activist investor Carl Icahn is preparing a proxy fight at Illumina Inc, arguing that the life science maker’s acquisition of Grail Inc cost its shareholders roughly $50 billion,…
(Reuters) – Illumina Inc said on Monday it was cutting 5% of its global workforce to realign its operating expenses as stubborn inflation and a strong dollar weigh on the…
(Reuters) – A judge has ruled in favor of Illumina Inc in its acquisition of Grail Inc dealing a blow to the U.S. Federal Trade Commission’s efforts to unwind the…
BRUSSELS – EU antitrust regulators are expected to veto U.S. life sciences firm Illumina’s acquisition of biotechnology company Grail, people familiar with the matter said on Wednesday. There are doubts…
By Foo Yun Chee LUXEMBOURG -U.S. life sciences company Illumina on Wednesday lost its challenge against European Union scrutiny of its $8 billion cash-and-stock takeover of Grail, as a top…
By Foo Yun Chee BRUSSELS – A European court will decide on July 13 whether U.S. life sciences company Illumina’s $8 billion cash-and-stock takeover of Grail should be scrutinised by…